Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04060173 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
A Phase 1 study, sponsored by Atom Therapeutics Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04060173 is a Phase 1 study that has completed, run by Atom Therapeutics Co.. The registered enrollment target is 27 participants.
The verdict
NCT04060173, a Phase 1 study, has completed, sponsored by Atom Therapeutics Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with hyperuricemia.
Interventions
- OTHER Placebo
- DRUG ABP-671
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2020-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04060173
The ClinicalTrials.gov registry entry for NCT04060173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atom Therapeutics Co., which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04060173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04060173 about?
NCT04060173 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671". The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with hyperuricemia.
What is the current status of trial NCT04060173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2019-09-05. Estimated completion is 2020-02-07.
What interventions are being tested in trial NCT04060173?
The interventions under investigation include: Placebo (OTHER), ABP-671 (DRUG).
Who is sponsoring clinical trial NCT04060173?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.